Navigating State Sales & Marketing Laws for Drugs & Medical Devices

Marketing your pharmaceutical product or medical device while adhering to ever-changing state and federal laws can pose a signifcant challenge. For example, on March 11, 2009 the Massachusetts Department of Public Health issued requirements similar to those of other states, imposing restrictions on pharmaceutical and medical device manufacturers’ sales and marketing activities. This session looks at current state laws regulating the sales and marketing practices of pharmaceutical, biotech and medical device companies, with a particular emphasis on the new requirements in Massachusetts and Vermont.

In this conference, our speaker examines the federal legislation that regulates pharmaceutical and medical device sales and marketing, while also providing insight into how companies can develop compliance plans to take into account the "patchwork" of state laws, applicable federal laws and industry guidance.

Navigating State Sales & Marketing Laws for Drugs & Medical Devices is being presented by Maria D. Buckley, with Nutter McClennen & Fish LLP and airs on Wednesday, November 4, 2009. For more details or to register to attend this event, please visit our site at www.fxconferences.com

The New Rules for CME Sponsors and Providers

There are new rules governing commercial support of Continuing Medical Education (CME) programs which affect both CME providers and industry supporters, such as pharmaceutical, biotech and medical device companies. With Congress scrutinizing industry support of CME, the ACCME has issued new guidance, as well as a “Call for Comment” on the issue of industry funding. The new PhRMA Code (effective January 2009), along with independent state laws, has been adjusted to govern relationships between industry and physicians. Life sciences organizations, as well as CME providers, must keep abreast of these changes to maintain their accreditation status and ensure their internal policies are consistent with the latest laws and guidance.

This audio conference addresses how the new rules affect sponsors and providers and the best practices needed to comply.

The New Rules for CME Sponsors and Providers was presented by Maria D. Buckley, Nutter McClennen & Fish LLP and aired on 2009-01-08. For more details or to download this audio conference, please visit our site at www.fxconferences.com

The New Rules for Continuing Medical Education

Both industry supporters (pharmaceutical, biotech and medical devices companies) and Continuing Medical Education providers have been affected by changes in the rules governing commercial support of CME programs. Industry support of CME has been scrutinized by Congress. The ACCME has issued new guidance, as well as a “Call for Comment,” on the issue of industry funding. The new PhRMA Code specifically addresses CME funding, as do certain state laws, most notably the new Massachusetts law governing relationships between industry and physicians.

Life sciences companies need to keep abreast of these changes to make sure their internal policies are consistent with the latest law and guidance. CME providers need to be current as well, both to maintain their accreditation status and to be sure they are able to remain competitive in the current environment. In this audio conference, we take a look at the new rules and what sponsors and providers need to do to comply.

The New Rules for Continuing Medical Education is being presented by Maria D. Buckley, with Nutter McClennen & Fish LLP and airs on Thursday, January 8, 2009. For more details or to register for this conference, please visit our site www.fxconferences.com